Veeva Systems: Opportunistic compounder at a discounted price
Durable compounder with exceptional margins, FCF, growth in a >25% drawdown
Executive Summary
Veeva is the quintessential vertical SaaS play: it sells cloud applications built specifically for life sciences, and over time it has inserted itself into workflows that are expensive, regulated, and hard to unwind. The market has been fixated on competitive pressure from Salesforce in Veeva’s CRM business. Because that story has visible “wins and losses,” and because you can point to customer churn and draw a straight line to sentiment, the equity is in a >25% drawdown since right before Q3 earnings. The current valuation implies a fundamental breakdown that isn't supported by the broader platform's durability.
CRM is important, but it is not “the company.” Veeva executives have said that CRM is ~20% of total revenue, emphasized the business is much broader than CRM alone, and marketshare within top 20 pharma customers is going from 90% to 70%. That’s not existential, and duopoloies (along with dupoloy multiples!) are great businesses. I see significant upside for Veeva as these competitive fears abate and the market re-prices the business as a durable compounder with AI tailwinds and notable upside.
Contents
Business Overview
CRM
What the Market is Missing (paywall)
Financial Projections (paywall)
Price Target (paywall)
Catalysts and Risks (paywall)
Business Overview
Veeva Systems | EV: $30.1bn | Sector: Healthcare Software | Position: long
Veeva (VEEV) is a vertical SaaS company that sells cloud software to life sciences companies (pharma, biotech, and increasingly adjacent categories) to run core workflows across commercialization and drug development. The business started with CRM, but today management frames Veeva as a portfolio of applications—growing from ~15 products in 2017 to ~50 today—so no single module “is the company.” The moat is structural: Veeva owns the data lineage and audit trails for compliance-critical workflows. Replacing Veeva isn’t a vendor swap, it’s a multi-year operational and regulatory migration. Below is a good summary of how the company views it’s own products and relative market share.
The suite spans a wide set of regulated, high-switching-cost workflows such as clinical data and operations tools like EDC (electronic data capture), RTSM (randomization / trial supply management), eTMF (electronic trial master file), quality systems, safety, and other specialized apps, many of which management still describes as early or mid-adoption with meaningful runway. Veeva makes money primarily from subscription software sold to enterprises, and the durability comes from being embedded in compliance-heavy processes where customers care about audit trails, data integrity, and “getting it right” more than shaving license dollars. A current debate is the CRM re-platforming: Veeva is migrating CRM from Salesforce’s platform to its own Vault platform (a process management expects to run 2022–2030). Veeva has lost 4 Top-20 pharma CRM customers (they had 18/20) during that transition as (in my view) the headache of switching for 20% of customers was too great. The Vault move also expands what Veeva can cross-sell, including new offerings and AI capabilities that weren’t feasible on Force.com.
CRM: Transition Friction vs. Structural Churn
Here’s how I think about the CRM debate:
The bear case is that the end of the Salesforce non-compete opens the door for competitive takeaways, and Veeva is forced to “re-win” customers during migration. The bear case centers on the Salesforce non-compete expiration, arguing that SMID/Biotech accounts will churn more aggressively than the Top-20 pharma cohort. No crystal ball here, but we do think this is a slightly over-blown risk to take the equity down >25%.
The bull case is not that churn disappears. It’s that the churn is (a) concentrated in a small set of very large customers, (b) plays out gradually over years, and (c) does not dominate Veeva’s overall economics because CRM is a minority of revenue. We think that Veeva’s products are specifically the best out there in pharma CRM, and more importantly the business is diversified with just ~20% of revenue related to CRM. There is an opportunity to win back customers over time, which we do not think the market is pricing this in at all.
What the market is missing: AI that is specific, auditable, and economically obvious
While most SaaS AI narratives are speculative, Veeva’s use cases are structural and immediate. Veeva is one of the most interesting exceptions because the “where it helps” use cases are painfully concrete. On recent calls, management has been explicit that customers want practical solutions now, including automating “Safety case processing” for adverse events. Given the sheer volume of manual documentation and reconciliation in pharma, AI agents capable of providing auditable workflow confirmations represent a massive productivity unlock, not just a 'nice-to-have' feature.
AI applications also seem economically obvious to me. Here are two examples:
Safety / Pharmacovigilance (PV): The outsourced PV market is cited as roughly $6B today, projected to double to ~$12B by 2030, with 60–70% of spend going to “case processing.” That’s exactly the kind of workflow that’s expensive, repetitive, and still full of humans triaging messy inputs. The ROI for pharma seems tangible and like an area that would get CTOs excited.
eTMF (trial master file). Building and maintaining an eTMF (~$2bn market annually) is deeply manual: collecting documents, classifying/indexing them, checking completeness/quality, and managing filing/version control. Management has put an internal stake in the ground: a goal to reduce the processing and outsourced labor around TMF by 50%. These would be massive, obvious savings that pharma would pay up for in my view.
Channel checks with clinicians (Internal Medicine, Orthopedics, Cardiology) suggest OpenEvidence has reached a tipping point in professional adoption. For those unfamiliar, this is the most widely used AI copilot for doctors, which cites medical research from JAMA, NEJM, and NCCN to name a few journals. 2025 was the year that the platform went mainstream (doctor and nurse use went up 830% in 2025 and the platform now supports >16m clinical consultations per month). In my view, 2026 should be the year where AI goes beyond clinical workflows and into commercialization and drug development. OpenEvidence recently raised $200m in series C funding at $6bn. For Veeva, with $6.4bn in net cash and capacity for another $3bn at 2x leverage, the company is a logical M&A target to accelerate a “Vertical Market AI” (VMAI) strategy.
Lastly, Veeva’s AI story is not “bolt on a chatbot.” JPM (in a recent report) emphasizes that Veeva’s agents will integrate natively within applications, operate within permissions and audit trails, and can be configured/extended by customers. This matters a lot more in life sciences than it does in generic SaaS, and in my view is solid rationale for vertical market solutions.
Financial Projections
To put it plainly: Veeva’s financials are best in class. 5-yuear revenue CAGR of 17%, FCF/net income conversion of ~110%, FCF margins of ~40%, all with ~1% dilution per year and an extremely defensive ($6.4bn net cash) balance sheet.
See my financial model and projections below. Management expects $6bn of run rate revenue by 2030 as they improve clinical productivity across life sciences by 20% over this period. I view their goal of >35% adj. EBIT margin as a pure floor and believe that it could trend toward 50%. I think the company can sustain 15% revenue growth over the next 24m, with potential further upside from the IQVIA partnership (a quiet positive where IQVIA data can now feed seamlessly into Veeva CRM, and IQVIA’s CRO can now use Veeva products) and AI product launches.
Of note, Rule of 40 is the typical software market measure of revenue growth rate + FCF margin, while Rule of X is a 2* rev growth +FCF margin measure.
To make your life easier, a few outputs from Veeva 2025 Investor Day:
Price Target: ~$400 | +83% | 27% IRR to CYE ‘27
I believe Veeva represents a highly attractive opportunity today and the market is over-extrapolating competitive pressures in 20% of the business resulting in a >25% selloff from before Q3 earnings on 11/20.
In the below, VEEV is trading at an undemanding 17.7x / 16.2x / 14.0x on ‘26 / ‘27 / ‘28 FCF. I view that as an extremely attractive entry point for a world-class business model with durable growth drivers and exceptional margins. Several other vertical market software businesses trade between 30-50x on 2027 FCF. IQV trades around a more reasonable ~20x FCF multiple. With Veeva’s long-term average forward P/E ratio between 25-30x, I am using a 27.5x FCF multiple on 2028 FCF for my price target. I view this as reasonable for the strong business quality and forward growth and attractive from a relative valuation perspective.
My temporal target is ~24 months (so end of CY 2027), when competitive fears in CRM have subsided and the market has digested that VEEV is actually an AI winner. I expect a re-rating toward historical FCF multiples (high-20s) as the market digests the AI-driven R&D growth and CRM stabilization. By mid 2028, the equity will be worth ~$400 or 83% higher than current levels, representing a 27% IRR to 6/30/2028.
Catalysts and Risks
Near-term Catalysts
AI agents move from announcement → adoption. I’m watching for tangible customer outcomes (cycle time reductions in content review, fewer compliance errors, measurable hours saved in Safety/TMF workflows). If the product is real, you’ll start to hear the same few use-cases repeated by customers and on calls.
CRM narrative stabilization. The market will keep scoring this like a sport: any non-Top-20 CRM decisions, any “won-back” dynamics, and whether Vault CRM migrations are progressing cleanly. I’m looking for churn to look bounded and explainable, not accelerating or spreading.
Commercial stack tightening. Watch integrations and ecosystem developments (including partners) that make Veeva harder to displace inside commercial workflows. These are the unsexy details that determine whether the suite feels “standard” or “optional.”
Medium-term Catalysts
AI becomes a pricing conversation. The upside isn’t AI buzz. It’s Veeva proving it can charge for automation as a layer on top of systems of record. The first version may be small dollars, but it should be directionally clear: does AI show up as incremental modules, usage-based pricing, or bundle uplift? How does that show up in revenue growth and margins?
R&D suite continues to widen. Large R&D wins can take time to ramp, but the leading indicators are expansion into adjacent workflows and evidence the suite is compounding even if one module is noisy.
CRM re-capture: There is potential for pharma customers to fully uproot Salesforce after seeing how strong Veeva’s products are. Transitioning could take take time (another 12-18mo) but would re-solidify Veeva’s monopoly position.
Risks
CRM churn becomes structural, not transitional.
The clean bear case is that the replatforming creates an opening and Salesforce (or others) turns that opening into persistent share loss. If churn moves from “a handful of large accounts” to “a broad pattern,” the market may be right to keep the multiple compressed.AI stays a feature, not a revenue line.
It’s entirely possible AI improves productivity but Veeva can’t monetize it meaningfully (customers expect it bundled; savings accrue to services partners; procurement blocks price uplift).R&D deal cycles are long and lumpy.
Even if Veeva is winning strategically, it can take years for large platform deals to translate into revenue. That can create “dead money” periods where fundamentals are fine but the stock doesn’t work.End-market softness hits at the wrong time.
Trial volumes, approvals, and biotech funding cycles matter. If the end market slows while CRM is already noisy, it can look like a business problem even if it’s mostly macro/industry timing.
I like Veeva because it allows you to be invested in the life sciences sector while still evaluating the company based on software metrics.